Table 4 Treatment and evolution “cure” in patients with loiasis: mono-therapy vs combined-therapy
From: Loiasis in sub-Saharan migrants living in Spain with emphasis of cases from Equatorial Guinea
N (%) (N = 102) | Cure | Adverse effects | Steroids n (%) (N = 44) | Anti-histaminic n (%) (N = 53) | |||
|---|---|---|---|---|---|---|---|
n (%) (N = 57) | P-value* OR (95% CI) | n (%) (N = 14) | P-value | ||||
Ivermectin | 58 (56.9) | 30 | 8 | 19 | 37 | ||
Ivermectin alone | 16 (15.7) | 0 | < 0.001* 3.5 (2.2–5.6) | 2/16 (12.5) | 0.860 | 4/16 (25.0) | 7/16 (43.8) |
Ivermectin with other antihelminth(s)a | 42 (41.2) | 30/42 (71.4) | 6/42 (14.3) | 15/42 (35.7) | 30/42 (71.4) | ||
Diethylcarbamazcine | 57 (55.9) | 50 | 10 | 32 | 40 | ||
Diethylcarbamazcine alone | 13 (12.7) | 9/13 (69.2) | 0.021* 6.0 (1.1–32.0) | 2/13 (15.4) | 0.816 | 9/13 (69.2) | 7/13 (53.8) |
Diethylcarbamazcine with other antihelminth(s)a | 44 (43.1) | 41/44 (93.2) | 8/44 (18.2) | 23/44 (52.3) | 33/44 (75.0) | ||
Albendazole | 20 (19.6) | 13 | 3 | 9 | |||
Albendazole | 8 (7.8) | 4/8 (50.0) | 0.251 3.0 (0.4–20.1) | 1/8 (12.5) | 0.798 | 5/8 (62.5) | 3/8 (37.5) |
Albendazole with other antihelminth(s)a | 12 (11.8) | 9/12 (75.0) | 2/12 (16.7) | 10/12 (83.3) | 6/12 (50.0) | ||
Mebendazole | 43 (42.1) | 5 | 10 | 21 | |||
Mebendazole alone | 9 (8.8) | 2/9 (22.2) | 0.022* 6.4 (1.1–35.9) | 0 | 0.221 | 0 | 0 |
Mebendazole with other antihelminth(s)a | 34 (33.3) | 22/34 (64.7) | 5/34 (14.7) | 10/34 (29.4) | 21/34 (61.8) | ||